SequelSEC

Replimune Group, Inc. REPL

Biological Products, (No Diagnostic Substances) · CIK 0001737953 · Fiscal year ends 0331

Revenue
Unavailable
Fiscal year ended 2026-03-31
Operating income
-$319.92M
Fiscal year ended 2026-03-31
Free cash flow
Unavailable
Fiscal year ended 2026-03-31

Replimune Group, Inc. (REPL) reported net income of -$313.94M for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Replimune Group, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Replimune Group, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$319.92M-$261.63M-$234.77M-$177.08M-$118.31M-$79.96M-$56.20M-$30.95M-$19.23M-$9.65M
Net income-$313.94M-$247.30M-$215.79M-$174.28M-$118.04M-$80.87M-$52.62M-$30.83M-$19.70M-$7.70M
Research & development$221.18M$189.45M$174.96M$126.53M$79.54M$56.75M$38.76M$22.17M$13.52M$6.94M
Weighted-average diluted sharesshares 92.80Mshares 80.56Mshares 66.57Mshares 58.21Mshares 52.21Mshares 46.25MUnavailableUnavailableUnavailableUnavailable
Pretax income-$314.49M-$246.83M-$215.39M-$174.00M-$118.04M-$80.87M-$52.62M-$30.83M-$19.70M-$7.70M
Income tax expense-$551.00K$468.00K$408.00K$288.00K$0$0$0$0$0$0
Diluted EPS$-3.38$-3.07$-3.24$-2.99$-2.26$-1.75UnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$98.74M$72.18MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailable$72.18M$59.81M$50.55M$38.77M$23.20M$17.44M$8.77M$5.71M$2.71M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Replimune Group, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Cash & equivalents$209.02M$111.12M$74.46M$146.59M$105.95M$182.52M$59.50M$25.70M$17.58MUnavailable
Total assets$332.39M$551.33M$487.72M$646.59M$461.19M$543.10M$234.10M$154.33M$65.15MUnavailable
Current assets$279.12M$495.88M$433.67M$592.60M$403.98M$483.75M$174.25M$140.98M$64.70MUnavailable
Total liabilities$166.23M$135.48M$113.21M$91.30M$49.96M$44.37M$50.38M$16.47M$6.86MUnavailable
Current liabilities$58.23M$62.36M$40.44M$33.82M$20.76M$14.55M$11.87M$9.88M$5.16MUnavailable
Total equity incl. NCI$166.16M$415.84M$374.51M$555.29M$411.23M$498.73M$183.72M$137.86M-$28.07M-$11.52M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$86.36MUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$83.31M$46.38M$44.81M$28.65M$0Unavailable$9.80MUnavailableUnavailableUnavailable
Accounts payable$6.67M$12.46M$2.58M$5.36M$3.73M$2.36M$3.43M$7.08M$1.99MUnavailable

Cash flow

Replimune Group, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Operating cash flow-$280.34M-$192.25M-$185.47M-$128.05M-$82.18M-$61.39M-$60.55M-$25.38M-$16.01M-$7.08M
Capital expendituresUnavailableUnavailableUnavailable$2.27M$2.34M$2.39M$6.54M$2.60M$136.00K$238.00K
Investing cash flow$310.84M-$23.80M$97.20M-$142.50M-$1.81M-$188.78M-$5.23M-$65.94M-$44.05M-$238.00K
Financing cash flow$66.29M$252.40M$16.28M$311.30M$6.60M$372.46M$100.17M$101.39M$54.75M$15.00M
Net change in cash$97.90M$36.66M-$72.07M$40.64M-$76.57M$123.02M$34.25M$9.23M-$3.01M$6.27M
Stock-based compensation$32.27M$35.04M$34.12M$28.13M$24.25M$11.79M$7.74M$2.73M$812.00K$208.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$3.33M$3.50M$2.66M$2.45M$2.15M$1.71M$533.00K$148.00K$109.00K$122.00K

Derived

Replimune Group, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailable-$84.52M-$63.78M-$67.09M-$27.98M-$16.15M-$7.32M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio4.79x7.95x10.72x17.52x19.46x33.25x14.68x14.26x12.53xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.50xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open REPL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-K · Filed 2026-06-29View SEC filing
10-Q · Filed 2026-02-03View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-K · Filed 2025-05-22View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.